<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2007-11-18" updated="2019-12-02">
  <drugbank-id primary="true">DB05685</drugbank-id>
  <name>FX06</name>
  <description>FX06 is a naturally occurring peptide derived from the neo-N-terminus of fibrin (Bbeta(15-42)). It prevents leukocyte migration through the gap junctions of endothelial cells. FX06 has proven safe in acute and subchronic toxicological studies and recently entered clinical development. It is being developed by Fibrex Medical Inc.</description>
  <cas-number/>
  <unii/>
  <state>liquid</state>
  <groups>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A3742</ref-id>
        <pubmed-id>17019083</pubmed-id>
        <citation>Atar D, Huber K, Rupprecht HJ, Kopecky SL, Schwitter J, Theek C, Brandl K, Henning R, Geudelin B: Rationale and design of the 'F.I.R.E.' study. A multicenter, double-blind, randomized, placebo-controlled study to measure the effect of FX06 (a fibrin-derived peptide Bbeta(15-42)) on ischemia-reperfusion injury in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Cardiology. 2007;108(2):117-23. Epub 2006 Oct 2.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Investigated for use/treatment in cardiac reperfusion injury and myocardial infarction.</indication>
  <pharmacodynamics/>
  <mechanism-of-action>FX06 has a novel mechanism of action: it is a competitive inhibitor of the binding of fibrin E1 fragments to vascular endothelial (VE)-cadherin. Through this inhibition, it potently blocks the transmigration of inflammatory leukocytes through the endothelial barrier and prevents the downstream release of tissue-damaging mediators.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms/>
  <products/>
  <international-brands/>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories/>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <sequences>
    <sequence format="FASTA">&gt;Fibrinogen beta chain (15-42) human
MKHLLLLLLCVFLVKSQGVNDNEEGFFS</sequence>
  </sequences>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347910191</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0003403</id>
      <name>Cadherin-5</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A3742</ref-id>
            <pubmed-id>17019083</pubmed-id>
            <citation>Atar D, Huber K, Rupprecht HJ, Kopecky SL, Schwitter J, Theek C, Brandl K, Henning R, Geudelin B: Rationale and design of the 'F.I.R.E.' study. A multicenter, double-blind, randomized, placebo-controlled study to measure the effect of FX06 (a fibrin-derived peptide Bbeta(15-42)) on ischemia-reperfusion injury in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Cardiology. 2007;108(2):117-23. Epub 2006 Oct 2.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P33151" source="Swiss-Prot">
        <name>Cadherin-5</name>
        <general-function>Receptor binding</general-function>
        <specific-function>Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. This cadherin may play a important role in endothelial cell biology through control of the cohesion and organization of the intercellular junctions. It associates with alpha-catenin forming a link to the cytoskeleton. Acts in concert with KRIT1 to establish and maintain correct endothelial cell polarity and vascular lumen. These effects are mediated by recruitment and activation of the Par polarity complex and RAP1B. Required for activation of PRKCZ and for the localization of phosphorylated PRKCZ, PARD3, TIAM1 and RAP1B to the cell junction.</specific-function>
        <gene-name>CDH5</gene-name>
        <locus>16q22.1</locus>
        <cellular-location>Cell junction</cellular-location>
        <transmembrane-regions>600-620</transmembrane-regions>
        <signal-regions>1-25</signal-regions>
        <theoretical-pi>5.07</theoretical-pi>
        <molecular-weight>87527.715</molecular-weight>
        <chromosome-location>16</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1764</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CDH5</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X79981</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P33151</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CADH5_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>7B4 antigen</synonym>
          <synonym>Vascular endothelial cadherin</synonym>
          <synonym>VE-cadherin</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037231|Cadherin-5
MQRLMMLLATSGACLGLLAVAAVAAAGANPAQRDTHSLLPTHRRQKRDWIWNQMHIDEEK
NTSLPHHVGKIKSSVSRKNAKYLLKGEYVGKVFRVDAETGDVFAIERLDRENISEYHLTA
VIVDKDTGENLETPSSFTIKVHDVNDNWPVFTHRLFNASVPESSAVGTSVISVTAVDADD
PTVGDHASVMYQILKGKEYFAIDNSGRIITITKSLDREKQARYEIVVEARDAQGLRGDSG
TATVLVTLQDINDNFPFFTQTKYTFVVPEDTRVGTSVGSLFVEDPDEPQNRMTKYSILRG
DYQDAFTIETNPAHNEGIIKPMKPLDYEYIQQYSFIVEATDPTIDLRYMSPPAGNRAQVI
INITDVDEPPIFQQPFYHFQLKENQKKPLIGTVLAMDPDAARHSIGYSIRRTSDKGQFFR
VTKKGDIYNEKELDREVYPWYNLTVEAKELDSTGTPTGKESIVQVHIEVLDENDNAPEFA
KPYQPKVCENAVHGQLVLQISAIDKDITPRNVKFKFILNTENNFTLTDNHDNTANITVKY
GQFDREHTKVHFLPVVISDNGMPSRTGTSTLTVAVCKCNEQGEFTFCEDMAAQVGVSIQA
VVAILLCILTITVITLLIFLRRRLRKQARAHGKSVPEIHEQLVTYDEEGGGEMDTTSYDV
SVLNSVRRGGAKPPRPALDARPSLYAQVQKPPRHAPGAHGGPGEMAAMIEVKKDEADHDG
DGPPYDTLHIYGYEGSESIAESLSSLGTDSSDSDVDYDFLNDWGPRFKMLAELYGSDPRE
ELLY</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012383|Cadherin-5 (CDH5)
ATGCAGAGGCTCATGATGCTCCTCGCCACATCGGGCGCCTGCCTGGGCCTGCTGGCAGTG
GCAGCAGTGGCAGCAGCAGGTGCTAACCCTGCCCAACGGGACACCCACAGCCTGCTGCCC
ACCCACCGGCGCCAAAAGAGAGATTGGATTTGGAACCAGATGCACATTGATGAAGAGAAA
AACACCTCACTTCCCCATCATGTAGGCAAGATCAAGTCAAGCGTGAGTCGCAAGAATGCC
AAGTACCTGCTCAAAGGAGAATATGTGGGCAAGGTCTTCCGGGTCGATGCAGAGACAGGA
GACGTGTTCGCCATTGAGAGGCTGGACCGGGAGAATATCTCAGAGTACCACCTCACTGCT
GTCATTGTGGACAAGGACACTGGCGAAAACCTGGAGACTCCTTCCAGCTTCACCATCAAA
GTTCATGACGTGAACGACAACTGGCCTGTGTTCACGCATCGGTTGTTCAATGCGTCCGTG
CCTGAGTCGTCGGCTGTGGGGACCTCAGTCATCTCTGTGACAGCAGTGGATGCAGACGAC
CCCACTGTGGGAGACCACGCCTCTGTCATGTACCAAATCCTGAAGGGGAAAGAGTATTTT
GCCATCGATAATTCTGGACGTATTATCACAATAACGAAAAGCTTGGACCGAGAGAAGCAG
GCCAGGTATGAGATCGTGGTGGAAGCGCGAGATGCCCAGGGCCTCCGGGGGGACTCGGGC
ACGGCCACCGTGCTGGTCACTCTGCAAGACATCAATGACAACTTCCCCTTCTTCACCCAG
ACCAAGTACACATTTGTCGTGCCTGAAGACACCCGTGTGGGCACCTCTGTGGGCTCTCTG
TTTGTTGAGGACCCAGATGAGCCCCAGAACCGGATGACCAAGTACAGCATCTTGCGGGGC
GACTACCAGGACGCTTTCACCATTGAGACAAACCCCGCCCACAACGAGGGCATCATCAAG
CCCATGAAGCCTCTGGATTATGAATACATCCAGCAATACAGCTTCATCGTCGAGGCCACA
GACCCCACCATCGACCTCCGATACATGAGCCCTCCCGCGGGAAACAGAGCCCAGGTCATT
ATCAACATCACAGATGTGGACGAGCCCCCCATTTTCCAGCAGCCTTTCTACCACTTCCAG
CTGAAGGAAAACCAGAAGAAGCCTCTGATTGGCACAGTGCTGGCCATGGACCCTGATGCG
GCTAGGCATAGCATTGGATACTCCATCCGCAGGACCAGTGACAAGGGCCAGTTCTTCCGA
GTCACAAAAAAGGGGGACATTTACAATGAGAAAGAACTGGACAGAGAAGTCTACCCCTGG
TATAACCTGACTGTGGAGGCCAAAGAACTGGATTCCACTGGAACCCCCACAGGAAAAGAA
TCCATTGTGCAAGTCCACATTGAAGTTTTGGATGAGAATGACAATGCCCCGGAGTTTGCC
AAGCCCTACCAGCCCAAAGTGTGTGAGAACGCTGTCCATGGCCAGCTGGTCCTGCAGATC
TCCGCAATAGACAAGGACATAACACCACGAAACGTGAAGTTCAAATTCATCTTGAATACT
GAGAACAACTTTACCCTCACGGATAATCACGATAACACGGCCAACATCACAGTCAAGTAT
GGGCAGTTTGACCGGGAGCATACCAAGGTCCACTTCCTACCCGTGGTCATCTCAGACAAT
GGGATGCCAAGTCGCACGGGCACCAGCACGCTGACCGTGGCCGTGTGCAAGTGCAACGAG
CAGGGCGAGTTCACCTTCTGCGAGGATATGGCCGCCCAGGTGGGCGTGAGCATCCAGGCA
GTGGTAGCCATCTTACTCTGCATCCTCACCATCACAGTGATCACCCTGCTCATCTTCCTG
CGGCGGCGGCTCCGGAAGCAGGCCCGCGCGCACGGCAAGAGCGTGCCGGAGATCCACGAG
CAGCTGGTCACCTACGACGAGGAGGGCGGCGGCGAGATGGACACCACCAGCTACGATGTG
TCGGTGCTCAACTCGGTGCGCCGCGGCGGGGCCAAGCCCCCGCGGCCCGCGCTGGACGCC
CGGCCTTCCCTCTATGCGCAGGTGCAGAAGCCACCGAGGCACGCGCCTGGGGCACACGGA
GGGCCCGGGGAGATGGCAGCCATGATCGAGGTGAAGAAGGACGAGGCGGACCACGACGGC
GACGGCCCCCCCTACGACACGCTGCACATCTACGGCTACGAGGGCTCCGAGTCCATAGCC
GAGTCCCTCAGCTCCCTGGGCACCGACTCATCCGACTCTGACGTGGATTACGACTTCCTT
AACGACTGGGGACCCAGGTTTAAGATGCTGGCTGAGCTGTACGGCTCGGACCCCCGGGAG
GAGCTGCTGTATTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00028</identifier>
            <name>Cadherin</name>
          </pfam>
          <pfam>
            <identifier>PF01049</identifier>
            <name>Cadherin_C</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>adherens junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>bicellular tight junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell-cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>external side of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>beta-catenin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ion channel binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adherens junction organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood vessel maturation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell junction assembly</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell-cell junction assembly</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell-cell junction organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>homophilic cell adhesion via plasma membrane adhesion molecules</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of establishment of endothelial barrier</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of establishment of cell polarity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transforming growth factor beta receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vascular endothelial growth factor receptor signaling pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>